Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Alkem Laboratories - Pick-up starts in acute portfolio - ICICI Securities

Posted On: 2021-01-10 04:43:08 (Time Zone: Arizona, USA)


Alkem Laboratories' (Alkem) has underperformed BSE Healthcare Index in the last one year mainly due to acute heavy portfolio which was impacted by COVID-19. In our view, this temporary impact on acute portfolio caused by the lockdown has already been captured in the stock's underperformance. However, as per AIOCD (secondary sales) data, anti-infectives and gastro-intestinal, the two largest therapeutic segments for Alkem, have witnessed healthy ramp-up in growth. Additionally, growth in FY22E may hold room for some positive surprise considering the low base of FY21. We remain positive on the long-term outlook based on sustainable growth in the domestic market and continuous scale-up in US generic business coupled with an improving margin profile. Reiterate Buy.

- Expect valuations to improve with ramp-up in growth: The stock price underperformance over the last one year has been primarily due to weak growth resulting from lockdown, which in our view, is temporary and does not have any structural or fundamental impact on the company's business. Alkem, relative to its peers, was more severely impacted as its product mix is dominated by the acute portfolio. However, growth turned positive in Sep'20 and recovered well in Q3FY21 as per AIOCD (secondary sales) data. Further, the company's top brands - Pan, Pan D, etc. have outperformed the respective segments indicating faster recovery, which would also lead to margin improvement.

- Recovery to continue in India business: India formulations business contributes ~67% of total revenues and Alkem has consistently outperformed industry growth over the years. However, FY21 is likely to be an underperforming year for Alkem due to high dependence on acute portfolio. However, we expect growth to recover from Q3FY21 and reach double-digit Q4FY21 onwards. Additionally, growth in FY22E may hold room for some positive surprise considering the low base of FY21. We estimate 3.5% growth in Alkem's India business in FY21E and ~12% growth in FY22E and FY23E each. We believe, cost savings witnessed in H1FY21 would be partially sustainable and benefit Alkem more vs peers given its higher proportion of India sales.

- Outlook: We expect Alkem to register 9.4% revenue and 15.7% PAT CAGRs over FY20-FY23E with margin expansion of 350bps to 21.2%. We expect EBITDA margin to rebase at 20%+ for Alkem vs ~17% earlier. Strong earnings growth coupled with reduced capex would aid free cashflow generation of ~Rs40bn over FY21E-FY23E. It would also drive RoE/RoCE higher to 19.6%/18.1% respectively by FY23E.

- Valuation and risks: We remain positive on Alkem considering strong India business model, growth recovery and improving margin profile. We maintain Alkem as one of our top picks and reiterate BUY with a target price of Rs3,566/share based on 26xSep'22E EPS. Key downside risks: regulatory hurdles and delay in product approvals in the US.

Shares of Alkem Laboratories Ltd was last trading in BSE at Rs.3038.45 as compared to the previous close of Rs. 3012.2. The total number of shares traded during the day was 6149 in over 934 trades.

The stock hit an intraday high of Rs. 3068.9 and intraday low of 2997.9. The net turnover during the day was Rs. 18690992.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Union Budget 2021-22 - Preview Report - YES SECURITIES

Alembic Pharma (Q3 FY21) - 'First signs of sartans weakness' - YES Securities

CSB Bank Q3 Earnings Call - Key Takeaways - YES Securities

ICICI Lombard - Q3FY21 Result Report - YES Securities

Gateway Distriparks - Q3FY21 - Multiple triggers at play - ICICI Securities

Prince Pipes and Fittings - Improving governance; rerating inevitable - ICICI Securities

CEAT - Margins resilient due to healthy replacement mix - ICICI Securities

Hatsun Agro Products - Commencement of three plants and lower tax rate to boost return ratios in FY22 and beyond - ICICI Securities

Alembic Pharmaceuticals - India recovers, US sees pressure - ICICI Securities

Q3FY21 Result update - MindTree Ltd - ICICI Direct

Q3FY21 Company update - Shoppers Stop - ICICI Direct

IPO - Indigo Paints Ltd - ICICI Direct

Larsen & Toubro Infotech Ltd - Q3FY21 First Cut - ICICI Direct

Tata Communications - Q3FY21 First Cut - ICICI Direct

Maintain ADD on Mindtree - Into another operating orbit - HDFC Securities

NBFCs Q3FY21 Results Preview - Micro headwinds > Macro tailwinds - HDFC Securities

Mindtree - Margin beat and raise cycle seems to be over! - ICICI Securities

Shoppers Stop - Focusing on omni-channel growth - ICICI Securities

Piramal Enterprises - Strategic synergies, optional value to follow DHFL's buyout - ICICI Securities

Motherson Sumi Systems - Focus remains on growth and cost efficiency - ICICI Securities

Metropolis Healthcare - Acquires Hitech Diagnostics in South India - ICICI Securities

Nifty PE shifting orbits - ICICI Direct

Rallis India Ltd - Q3FY21 First Cut - ICICI Direct

Q3FY21 Company update - GTPL Hathway - ICICI Direct

Q3FY21 Result update - HDFC Bank - ICICI Direct

Q3FY21 Result Update - PVR Ltd - ICICI Direct

Q3FY21 Result update - HCL Technologies - ICICI Direct

Maintain BUY on HCL Technologies - Mode-2, 3 driven momentum - HDFC Securities

HDFC Bank Q3FY21 Results - Concall Highlights and Views of YES SECURITIES

HDFC Bank Q3 FY21 - 'Stellar Show' - Retain BUY and raise 12m PT to Rs1870 - YES Securities

IPO Review - Indian Railway Finance Corporation (IRFC) - ICICI Direct

HCL Technologies - Q3FY21 First Cut - ICICI Direct

Logistics Sector Update - Indian Railways - getting aggressive - HDFC Securities

Indigo Paints - IPO view - YES SECURITIES

Infosys - Near-term margins will likely come under pressure - ICICI Securities

CESC - 7% dividend yield + higher ESG rating - ICICI Securities

South Indian Bank - Unveils vision 2024; targets RoA / RoE of 1% / 13% by 2024 - ICICI Securities

Maintain BUY on Infosys - Growth certainty on explosive deal wins - HDFC Securities

Maintain ADD on Wipro - Growth acceleration - HDFC Securities

Consumer Durables - Q3FY21 Results Preview - HDFC Securities

Q3FY21 Company Update - Filatex India - ICICI Direct

Q3FY21 Result Update - Wipro Ltd - ICICI Direct

Q3FY21 Result Update - CESC - ICICI Direct

Monthly Inflation - December 2020 - ICICI Direct

Q3FY21 Result Update - Infosys - ICICI Direct

Banks Q3FY21 Results Preview - Scope for optimism beyond a tepid 3Q - HDFC Securities

Consumer Discretionary Companies - Q3FY21 Results Preview Report - HDFC Securities

Pharma Sector Update - Ample catalysts to sustain luster - HDFC Securities

Suman Chowdhury, Chief Analytical Officer, Acuité Ratings & Research on IIP data

Infosys - Q3FY21 First Cut - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020